特异性环氧化酶2与肾细胞癌血管增生的相关性研究  

Research on the correlation of COX-2 and renal cell carcinoma

作　　者：裴维芳[1] 李红霞[2] 李玉萍[2] 

机构地区：[1]滨州市人民医院介入医学科,山东省滨州256610 [2]滨州市人民医院创伤骨科,山东省滨州256610

出　　处：《中国基层医药》2012年第10期1460-1461,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的探讨特异性环氧化酶2（COX-2）在肾细胞癌的表达及其与肾细胞癌血管增生的关系。方法免疫组化检测肾细胞癌组织标本（85例）以及癌旁正常组织标本（48例）COX一2、血管内皮生长因子（VEGF）和碱性成纤维细胞生长因子（bFGF）的表达，CD34单克隆抗体标记血管内皮细胞进行微血管密度（MVD）计数。结果COX-2、VEGF和bFGF在癌旁正常组织中阳性表达率分别为16．7％，20．8％和22．9％，在肾细胞癌组织阳性表达率分别为77．6％、80．0％和74．1％，两组差异均有统计学意义（均P〈0．01）。肾癌组织MVD为（55．47±18．47），高于癌旁正常组织的（20．42±8．72）（P〈0．01）。COX-2、VEGF、bFGF表达阳性的肾细胞癌其MVD均大于表达阴性的肾细胞癌MVD（P〈0．05或P〈0．01）。肾细胞癌组织COX-2表达与VEGF、bFGF表达呈显著正相关（P〈0．01）。结论COX-2在肾细胞癌组织中表达升高，与肾细胞癌血管增生密切相关。Objective To explore the expression of Cyclooxygenase-2-specific（COX-2） in renal cell carcinoma and its relationship with angiogenesis. Methods The expression of COX-2, VEGF and bFGF in renal cell carcinoma specimens（85 cases） and adjacent normal tissue samples（48 cases） was measured by immunohistochemistry. Microvessel density （MVD） was evaluated by immunohistochemistry using a monoclonal antibody against CD34. Results The positive expression rates of COX-2, VEGF and bFGF in adjacent normal tissue were 16.7% , 20.8% , 22.9% , and 77.6% , 80.0% ,74.1% in renal cell carcinoma, respectively, the difference, were significant （ all P 〈 0. 01 ）. MVD was（55.47 ±18.47 ） Counts/field in renal cell carcinoma, and（20. 42 ±8.72） Counts/field in adjacent normal tissue,the difference was significant（ P 〈 0.01 ）. MVD in renal cell carcinoma which was positive expressed COX-2,VEGF,bFGF was higher than renal cell carcinoma which was negative expressed COX-2, VEGF, bFGF, the difference was significantly statistical （P 〈 0.05 or P 〈 0.01 ）. COX-2 expression and VEGF, bFGF in renal cell carcinoma expression was positively correlated（ P 〈 0.01 ）. Conclusion COX-2 expression was elevated in renal cell carcinoma,and it was related closely with renal cell carcinoma angiogenesis.

关 键 词：肾肿瘤 血管增生 特异性环氧化酶2 血管内皮生长因子 成纤维细胞生长因子 微血管密度 

分 类 号：R737.11[医药卫生—肿瘤]